Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kim, Hani ^a,b   Gillis, Lisa C ^a,b   Jarvis, Jordan D ^a,b   Yang, Stuart ^b   Huang, Kai ^a   Der, Sandy ^b   Barber, Dwayne L ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE; TEL JANUS KINASE 2; TEL PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TEL JAK2 FUSION PROTEIN, HUMAN; TEL PDGFRBETA FUSION PROTEIN, HUMAN; TEL-JAK2 FUSION PROTEIN, HUMAN; TEL-PDGFRBETA FUSION PROTEIN, HUMAN;

ARTICLE; CELL ACTIVATION; CELL LINE; CHROMOSOME TRANSLOCATION; COL5A1 GENE; CONTROLLED STUDY; CXCL10 GENE; DOK2 GENE; GBP1 GENE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; GENE PRODUCT; GENE REPRESSION; GP49B GENE; ISG20 GENE; LD1 GENE; MICROARRAY ANALYSIS; MRVI1 GENE; SCINDERIN GENE; STAT1 GENE; TRANSCRIPTION REGULATION; DNA MICROARRAY; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; HUMAN; LEUKEMIA; METABOLISM; METHODOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RNA, MESSENGER; TRANSLOCATION, GENETIC;

EID: 84455193327     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-528     Document Type: Article

References (69)

1. Konopka J, Watanabe S, Witte O. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035-1042.
2. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316. 10.1016/0092-8674(94)90322-0, 8168137.
3. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Sci 1997, 278(5341):1309-1312.
4. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90(7):2535-2540.
5. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996, 183(3):811-820. 10.1084/jem.183.3.811, 2192351, 8642285.
6. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996, 10(11):1724-1730.
7. Ilaria RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271(49):31704-31710. 10.1074/jbc.271.49.31704, 8940193.
8. Chai S, Nichols G, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997, 159(10):4720-4728.
9. Shuai K, Halpern J, Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13:247-254.
10. Ho JM, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 1999, 93(12):4354-4364.
11. Wilbanks A, Mahajan S, Frank D, Druker B, Gilliland D, Carroll M. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol 2000, 28:584-593. 10.1016/S0301-472X(00)00138-7, 10812249.
12. Sternberg DW, Tomasson MH, Carroll M, Curley DP, Barker G, Caprio M, Wilbanks A, Kazlauskas A, Gilliland DG. The TEL/PDGFbeta R fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood 2001, 98(12):3390-3397. 10.1182/blood.V98.12.3390, 11719379.
13. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011, 117(12):3421-3429. 10.1182/blood-2009-11-255232, 21233313.
14. Mahlmann S, McLaughlin J, Afar DE, Mohr R, Kay RJ, Witte ON. Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection. Leukemia 1998, 12(12):1858-1865. 10.1038/sj.leu.2401231, 9844916.
15. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002, 1(5):479-492. 10.1016/S1535-6108(02)00074-0, 12124177.
16. Ho JM, Nguyen MH, Dierov JK, Badger KM, Beattie BK, Tartaro P, Haq R, Zanke BW, Carroll MP, Barber DL. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 2002, 100(4):1438-1448.
17. Atfi A, Prunier C, Mazars A, Defachelles AS, Cayre Y, Gespach C, Bourgeade MF. The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway. Oncogene 1999, 18(26):3878-3885. 10.1038/sj.onc.1202734, 10445851.
18. Wheadon H, Welham MJ. The coupling of TEL/PDGF{beta}R to distinct functional responses is modulated by the presence of cytokine: involvement of mitogen-activated protein kinases. Blood 2003, 102(4):1480-1489. 10.1182/blood-2002-09-2974, 12714513.
19. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3 k/Akt-dependent pathway. Embo J 1997, 16(20):6151-6161. 10.1093/emboj/16.20.6151, 1326299, 9321394.
20. Nguyen MH, Ho JM, Beattie BK, Barber DL. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway. J Biol Chem 2001, 276(35):32704-32713. 10.1074/jbc.M103100200, 11435425.
21. Dierov J, Xu Q, Dierova R, Carroll M. TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood 2002, 99(5):1758-1765. 10.1182/blood.V99.5.1758, 11861293.
22. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009, 23(8):1432-1440. 10.1038/leu.2009.49, 19295548.
23. Ren R. Mechanism of Bcr-Abl in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183. 10.1038/nrc1567, 15719031.
24. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005, 90:949-968.
25. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathwyas in hematologic malignancies. Haematologica 2005, 90:949-968.
26. Van Etten R, Shannon K. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 2004, 6:547-552. 10.1016/j.ccr.2004.12.004, 15607959.
27. Steer E, Cross N. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002, 107:113-122. 10.1159/000046641, 11919393.
28. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. PNAS 1998, 95(25):14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
29. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105(7):2640-2653. 10.1182/blood-2004-08-3097, 15618470.
30. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112(13):4808-4817. 10.1182/blood-2008-07-077958, 19064740.
31. Salgia R, Brunkhorst B, Pisick E, Li J, Lo S, Chen L, Griffin J. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995, 11:1149-1144.
32. Nowicki M, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 2003, 22:3952-3963. 10.1038/sj.onc.1206620, 12813469.
33. Der SD, Zhou A, Williams BRG, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. PNAS 1998, 95(26):15623-15628. 10.1073/pnas.95.26.15623, 28094, 9861020.
34. Ohmine K, Ota J, Ueda M, Ueno S, Yoshida K, Yamashita Y, Kirito K, Imagawa S, Nakamura Y, Saito K, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 2001, 20:8249-8257. 10.1038/sj.onc.1205029, 11781839.
35. Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, Blanco E, Roes N, Graf T, Brors B, et al. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene 2005, 24:5313-5324. 10.1038/sj.onc.1208596, 15806158.
36. Advani A, Dressman H, Quiroz M, Taylor G, Pendergast A. Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis. Leuk Res 2004, 28:285-294. 10.1016/S0145-2126(03)00264-9, 14687624.
37. Yong ASM, Szydlo RM, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006, 107(1):205-212. 10.1182/blood-2005-05-2155, 16144796.
38. Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest S, Bruennert D, Huenerlituerkoglu AN, Stoecklein NH, Singh R, et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009, 23(5):892-899. 10.1038/leu.2008.392, 19158832.
39. Vianello F, Villanova F, Tisato V, Lymperi S, Ho KK, Gomes AR, Marin D, Bonnet D, Apperley J, Lam EW, et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica 2010, 95(7):1081-1089. 10.3324/haematol.2009.017178, 2895031, 20179085.
40. Nardi V, Naveiras O, Azam M, Daley GQ. ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood 2009, 113(16):3813-3820. 10.1182/blood-2008-07-167189, 2670796, 19171873.
41. Eaves C, Cashman J, Wolpe S, Eaves A. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. PNAS 1993, 90:12015-12019. 10.1073/pnas.90.24.12015, 48116, 8265663.
42. Wark G, Heyworth C, Spooncer E, Czaplewski L, Francis J, Dexter T, Whetton A. Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha. Oncogene 1998, 16:1319-1324. 10.1038/sj.onc.1201914, 9546433.
43. Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999, 94(12):4233-4246.
44. Chen YY, Malik M, Tomkowicz BE, Collman RG, Ptasznik A. BCR-ABL1 alters SDF-1alpha-mediated adhesive responses through the beta2 integrin LFA-1 in leukemia cells. Blood 2008, 111(10):5182-5186. 10.1182/blood-2007-10-117705, 2384141, 18339898.
45. Ptasznik A, Urbanowska E, Chinta S, Costa MA, Katz BA, Stanislaus MA, Demir G, Linnekin D, Pan ZK, Gewirtz AM. Crosstalk Between BCR/ABL Oncoprotein and CXCR4 Signaling through a Src Family Kinase in Human Leukemia Cells. J Exp Med 2002, 196(5):667-678. 10.1084/jem.20020519, 2193994, 12208881.
46. Arm J, Gurish M, Reynolds D, Scott H, Gartner C, Austen K, Katz H. Molecular cloning of gp49, a cell-surface antigen that is preferentially expressed by mouse mast cell progenitors and is a new member of the immunoglobulin superfamily. J Biol Chem 1991, 266(24):15966-15973.
47. Daheshia M, Friend DS, Grusby MJ, Austen KF, Katz HR. Increased Severity of Local and Systemic Anaphylactic Reactions in gp49B1-deficient Mice. J Exp Med 2001, 194(2):227-234. 10.1084/jem.194.2.227, 2193448, 11457897.
48. Katz HR, Vivier E, Castells MC, McCormick MJ, Chambers JM, Austen KF. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity Fc receptor for†IgE. PNAS 1996, 93(20):10809-10814. 10.1073/pnas.93.20.10809, 38237, 8855262.
49. Iida S, Kohro T, Kodama T, Nagata S, Fukunaga R. Identification of CCR2, flotillin, and gp49B genes as new G-CSF targets during neutrophilic differentiation. J Leukoc Biol 2005, 78(2):481-490. 10.1189/jlb.0904515, 15894583.
50. Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol 2000, 19:319-323. 10.1016/S0945-053X(00)00076-7, 10963992.
51. Gordon M, Dowding C, Riley G, Goldman J, Greaves M. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987, 328:342-344. 10.1038/328342a0, 3474529.
52. Bhatia R, Wayner E, McGlave P, Verfaillie C. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest 1994, 94:384-391. 10.1172/JCI117333, 296320, 7518835.
53. Bhatia R, Verfaillie CM. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta 1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998, 91(9):3414-3422.
54. Verfaillie C, McCarthy J, McGlave P. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992, 90:1232-1241. 10.1172/JCI115985, 443164, 1383271.
55. Verfaillie C, Hurley R, Lundell B, Zhao C, Bhatia R. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?. Acta Haematol 1997, 97:40-52. 10.1159/000203658, 8980609.
56. Chan J, Watt S. Adhesion receptors on haematopoietic progenitor cells. Brit J Haematol 2001, 112:541-557.
57. Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, et al. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010, 28(6):1017-1024. 10.1200/JCO.2009.24.1893, 2834428, 20048181.
58. Wisniewski D, Strife A, Swendeman S, Erdjument-Bromage H, Geromanos S, Kavanaugh WM, Tempst P, Clarkson B. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 1999, 93(8):2707-2720.
59. Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh MD, Pope RM. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics 2006, 6(16):4554-4564. 10.1002/pmic.200600109, 16858728.
60. Master Z, Tran J, Bishnoi A, Chen SH, Ebos JM, Van Slyke P, Kerbel RS, Dumont DJ. Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization. J Biol Chem 2003, 278(32):30170-30179. 10.1074/jbc.M301339200, 12777393.
61. Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, Osawa M, Honda K, Shinohara H, Sudo K, Tsuji K, et al. Role of Dok-1 and Dok-2 in Myeloid Homeostasis and Suppression of Leukemia. J Exp Med 2004, 200(12):1681-1687. 10.1084/jem.20041247, 2211997, 15611294.
62. Yasuda M, Theodorakis P, Subramanian T, Chinnadurai G. Adenovirus E1B-19 K/BCL-2 Interacting Protein BNIP3 Contains a BH3 Domain and a Mitochondrial Targeting Sequence 10.1074/jbc.273.20.12415. J Biol Chem 1998, 273(20):12415-12421. 10.1074/jbc.273.20.12415, 9575197.
63. Rodriguez del Castillo A, Vitale M, Tchakarov L, Trifaró J. Human platelets contain scinderin, a Ca2+-dependent actin filament-severing protein. Thromb Haemost 1991, 67:248-251.
64. Unwin RD, Sternberg DW, Lu Y, Pierce A, Gilliland DG, Whetton AD. Global effects of BCR/ABL and TEL/PDGFR-beta expression on the proteome and phosphoproteome: identification of the rho pathway as a target of BCR/ABL. J BiolChem 2005, 280(8):6316-6326.
65. Zunino R, Li Q, Rose SD, Romero-Benitez MMI, Lejen T, Brandan NC, Trifaro J-M. Expression of scinderin in megakaryoblastic leukemia cells induces differentiation, maturation, and apoptosis with release of plateletlike particles and inhibits proliferation and tumorigenesis. Blood 2001, 98(7):2210-2219. 10.1182/blood.V98.7.2210, 11568009.
66. Tam WF, Gu TL, Chen J, Lee BH, Bullinger L, Frohling S, Wang A, Monti S, Golub TR, Gilliland DG. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 2008, 112(5):1981-1992. 10.1182/blood-2007-07-103010, 2518899, 18559972.
67. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005, 5:603-614. 10.1038/nrc1673, 16034366.
68. Xu M, Nie L, Kim S, Sun X. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J 2003, 22:893-904. 10.1093/emboj/cdg094, 145454, 12574125.
69. Cain JA, Xiang Z, O'Neal J, Kreisel F, Colson A, Luo H, Hennighausen L, Tomasson MH. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 2007, 109(9):3906-3914. 10.1182/blood-2006-07-036335, 1874559, 17218386.